Group 1 - The CRO sector led the market with a rise of 3.5% on September 30 [1] - Haoyuan Pharmaceutical increased by 6.58% [1] - WuXi AppTec rose by 6.21% [1] - Boteng Co., Ltd. saw an increase of 4.99% [1] - MediSci and Northgrip, as well as Chengda Pharmaceutical, all experienced gains exceeding 4% [1]

股价刚创新高，股东减持接踵而至。 9月26日，光模块龙头中际旭创（300308.SZ）发布公告称，公司控股股东中际投资计划未来三个月减持 公司股份不超过550万股，占公司总股本的0.49%。 就在近期，公司股价触及457元的历史新高，截至9月26日收盘报413.7元，若按照最新收盘价计，此次 减持套现金额约22亿元。 公司股价站上历史高位之际，控股股东选择"落袋为安"。这并非孤例。记者据Wind不完全统计，仅本 周末（9月26日至28日），A股市场就有100家上市公司密集发布减持公告，涉及硬件设备、半导体、医 药生物、消费等热门赛道。 股价翻数倍，股东"组团"减持 具体看来，中际旭创公告显示，中际投资合计持有公司股份1.27亿股，占公司总股本的11.42%，本次减 持以大宗交易方式进行。中际投资及其一致行动人承诺，自本次减持计划完成后12个月内不减持公司股 份。 公司9月17日晚间公告显示，7月1日至9月17日，特定股东苏州益兴福企业管理中心（有限合伙，下 称"益兴福"）及其一致行动人，总共减持该公司463.41万股，合计持股比例由9.417%减少至8.9999%。 按照三季度股价均值300元计，益兴福可能套 ...

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [1][33]. Core Insights - The pharmaceutical and biotechnology sector experienced an overall decline of 2.07% from September 15 to September 19, ranking 23rd among 31 industries in the Shenwan index, underperforming the CSI 300 index by 1.63 percentage points. Year-to-date, the sector has risen by 24.17%, ranking 10th among the 31 industries and outperforming the CSI 300 index by 9.76 percentage points [3][12][16]. - The current PE valuation for the pharmaceutical and biotechnology sector stands at 31.18 times, which is at the historical median level, with a valuation premium of 136% compared to the CSI 300 index [3][19]. - The report highlights significant policy developments, including the completion of the review for the 2025 National Basic Medical Insurance Directory and the formal release of the 11th batch of national procurement documents, which includes 55 major varieties [4][27][28]. Market Performance - The pharmaceutical and biotechnology sector's performance for the week of September 15-19 showed a decline of 2.07%, with the top three declining sub-sectors being biological products (-3.47%), chemical pharmaceuticals (-2.43%), and traditional Chinese medicine II (-2.13%) [3][12]. - Year-to-date, the sector has increased by 24.17%, with the top three performing sub-sectors being medical services (46.19%), chemical pharmaceuticals (41.47%), and biological products (16.75%) [16][19]. Industry News - On September 20, the National Medical Insurance Administration completed the review of the 2025 National Basic Medical Insurance Directory and the commercial insurance innovative drug directory, moving into the core negotiation and pricing phase [4][27]. - The 11th batch of national procurement was officially released on September 20, optimizing the requirements for bidding companies and the rules for procurement, which is expected to be a significant turning point for the industry [4][28]. - The Shanghai Municipal Government issued a plan to promote the development of the high-end medical device industry, aiming to enhance innovation and international competitiveness by 2027 [4][29]. Investment Recommendations - The report suggests focusing on the progress of the medical insurance directory negotiations and the implications of the national procurement policies. It recommends investment opportunities in innovative drugs, CXO, medical devices, traditional Chinese medicine, chain pharmacies, and medical services [5][30]. - Recommended stocks include Teva Biopharmaceuticals, Rongchang Biopharmaceuticals, Betta Pharmaceuticals, Kaili Medical, and Huaxia Eye Hospital, with additional stocks to watch including Kelun Pharmaceutical, Qianhong Pharmaceutical, Yifeng Pharmacy, Baipusais, and Lingrui Pharmaceutical [5][30].

Investment Rating - The report does not explicitly state an investment rating for the pharmaceutical and biotechnology industry, but it provides insights into market performance and trends [1]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 2.07% from September 15 to September 19, underperforming compared to the Wind All A index (-0.18%) and the CSI 300 index (-0.44%) [2][7]. - The only sub-sector that saw an increase was medical research outsourcing, which rose by 1.09%, while other segments such as biological products (-3.83%), vaccines (-3.64%), and in vitro diagnostics (-3.41%) faced declines [2][7]. - The National Healthcare Security Administration released the 11th batch of centralized drug procurement documents on September 20, emphasizing principles of "stabilizing clinical use, ensuring quality, preventing price wars, and countering internal competition" [2][10]. - The new procurement policy aims to optimize price control mechanisms and reduce the financial pressure on pharmaceutical companies by shortening the payment cycle through prepayments from healthcare insurance agencies [2][10]. Weekly Market Review - The pharmaceutical and biotechnology sector's performance from September 15 to September 19 showed a decline of 2.07%, with medical research outsourcing being the only sub-sector to gain [7]. - Notable stock performances included Yinos (23.3%), Furuida (17.8%), and Chengda Pharmaceutical (14.6%) as top gainers, while Anglikang (-13.4%), Nentech (-12.6%), and Shutaishen (-12.3%) were the biggest losers [10]. Industry News and Key Company Announcements - The report highlights significant industry events, including the release of centralized procurement documents and the announcement of various clinical trials and acquisitions by companies such as Roche and Innovent Biologics [11][14]. - The Sichuan Provincial Medical Insurance Bureau introduced a new online settlement management method for centralized procurement, which aims to improve cash flow for pharmaceutical companies [14]. - Companies like Watson Bio and Maiwei Biologics received clinical trial approvals for their respective products, indicating ongoing innovation and development within the industry [15].

证券日报网讯 9月19日晚间，诚达药业发布公告称，本次保荐代表人更换后，公司首次公开发行股票并 在创业板上市项目的持续督导保荐代表人为杨科先生、韩剑龙先生。 （文章来源：证券日报） ...

诚达药业股份有限公司（以下简称"公司"）于近日收到公司保荐机构光 大证券股份有限公司（以下简称"光大证券"）出具的《关于更换诚达药业股份 有限公司保荐代表人的报告》，保荐代表人范国祖先生因工作变动原因，不再负 责公司首次公开发行股票并在创业板上市的持续督导工作。为保证持续督导工作 的有序进行，光大证券决定由韩剑龙先生（简历详见附件）接替范国祖先生的持 续督导工作，继续履行督导职责。 本次保荐代表人更换后，公司首次公开发行股票并在创业板上市项目的持续 督导保荐代表人为杨科先生、韩剑龙先生。公司首次公开发行股票并在创业板上 市的持续督导期将于 2025 年 12 月 31 日到期。届时如公司募集资金尚未使用完 毕，光大证券对募集资金使用情况将继续履行持续督导义务。持续督导期限至持 续督导义务结束之日止。 公司董事会对范国祖先生在公司首次公开发行股票并在创业板上市的持续 督导期间所作的工作表示衷心感谢！ 特此公告。 诚达药业股份有限公司董事会 2025 年 9 月 19 日 附件：韩剑龙先生简历 证券代码：301201 证券简称：诚达药业 公告编号：2025-034 诚达药业股份有限公司 关于更换持续督导保荐代表人 ...

Core Viewpoint - L-Carnitine is increasingly recognized as a crucial "conditional nutrient" that aids in fat metabolism and energy production, leading to a growing demand in the health and fitness market [1][4][11] Industry Definition and Production Process - L-Carnitine is a naturally occurring amino acid that transports long-chain fatty acids into mitochondria for energy production, playing a vital role in energy metabolism [2][3] - The main production methods include direct extraction, chemical synthesis, enzymatic conversion, and bacterial fermentation [3][6] Current Industry Status - The demand for L-Carnitine in China is projected to grow from 1,343 tons in 2018 to 3,171 tons in 2024, with the market size increasing from 21.165 billion yuan to 39.060 million yuan [5] - China has become the largest producer and exporter of L-Carnitine globally, with production expected to reach 10,043 tons and exports to 6,872 tons in 2024 [5][6] Industry Supply Chain - Early production methods relied on animal sources, which were inefficient and costly, leading to the adoption of more effective methods [6] - L-Carnitine can be synthesized in the body but is often supplemented in specific populations such as athletes, vegetarians, and the elderly [6] Competitive Landscape - Major players in the Chinese L-Carnitine market include Guangzhou Longsha Pharmaceutical Co., Northeast Pharmaceutical Group, and Chengda Pharmaceutical Co., with Chengda being the largest producer [7][9] - Chengda Pharmaceutical's production capacity is around 4,000 tons annually, making it a significant global supplier [9] Industry Development Trends - The market for L-Carnitine is expected to grow steadily due to increasing health awareness and an aging population [11] - Future trends indicate a diversification of L-Carnitine products to cater to personalized health management and a broader range of applications [11]

Core Insights - The medical services sector experienced a slight increase of 0.29% on September 16, with Chengda Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3861.87, up 0.04%, while the Shenzhen Component Index closed at 13063.97, up 0.45% [1] Medical Services Sector Performance - Chengda Pharmaceutical (301201) closed at 33.32, with a significant increase of 15.25% and a trading volume of 157,100 shares, amounting to a transaction value of 508 million yuan [1] - Haocen Medical (002622) saw a rise of 10.10%, closing at 4.25 with a trading volume of 993,200 shares, totaling 409 million yuan [1] - Aoyang Health (002172) increased by 10.00%, closing at 4.73 with a trading volume of 87,500 shares, amounting to 41.39 million yuan [1] - Bid Pharma (688073) rose by 6.48%, closing at 74.73 with a trading volume of 26,000 shares, totaling 192 million yuan [1] - Yikang Biological (688046) increased by 5.56%, closing at 19.75 with a trading volume of 79,600 shares, amounting to 158 million yuan [1] - Other notable performers include Haoyuan Pharmaceutical (688131) with a 4.44% increase, closing at 78.28, and Xinlicheng (002219) with a 3.46% increase, closing at 2.39 [1] Fund Flow Analysis - The medical services sector saw a net outflow of 228 million yuan from institutional investors, while retail investors contributed a net inflow of 59.64 million yuan [3] - Speculative funds recorded a net inflow of 168 million yuan into the sector [3]

| （1）是否存在需要关注的事项 | 是 2025 年 1-6 月，公司实现营业收入 | | --- | --- | | | 18,245.30 万 元 ， 较 上 年 同 期 增 长 | | | 11.24%；归属于上市公司股东的净利 | | | 润 万元，较上年同期下降 1,282.44 | | | 49.06%；归属于上市公司股东的扣除 | | （2）关注事项的主要内容 | 非经常性损益后的净利润 万 289.90 | | | 元，较上年同期下降 8.37%。 | | | 公司净利润较上年同期下降，主要 | | | 由于公司募投项目工程交付新增折旧 | | | 导致管理费用增加，以及报告期内投 | | | 资收益下降等原因所致。 | | | 保荐机构将持续关注上市公司的 | | （3）关注事项的进展或者整改情况 | 业绩情况，并督导上市公司按照相关 | | | 法律法规履行信息披露义务。 | | 9.保荐业务工作底稿记录、保管是否合规 | 是 | | 10.对上市公司培训情况 | | | （1）培训次数 | 0 次，拟下半年开展培训 | | （2）培训日期 | 不适用 | | （3）培训的主要内容 | ...

Group 1: Pharmaceutical Companies and Products - 63 pharmaceutical companies have been exposed for serious credit violations, with 63 companies rated as "particularly serious" or "serious" by the National Medical Insurance Administration [1] - Junshi Biosciences announced positive results from a Phase III clinical trial of JS005 for moderate to severe plaque psoriasis, planning to submit a marketing application soon [1] - Sanofi's teplizumab injection has been approved in China for delaying the progression of type 1 diabetes in patients aged 8 and above [2] Group 2: Corporate Actions - Yingke Medical adjusted its share repurchase price limit from RMB 26.51 to RMB 41.88 per share, effective from September 8, 2025, with a total repurchase fund of RMB 80 million to 120 million [3] - Qidi Pharmaceutical plans to change its name to "Guhan Health Industry Group Co., Ltd." and will revise its articles of association accordingly [4] - Jiuan Medical intends to cancel 9.77 million shares, which is 2.06% of its total share capital, as part of a strategy to enhance shareholder returns [5] Group 3: Market Movements and Regulations - Xiangrikui is planning to acquire controlling stakes in Xi Pu Materials and 40% of Beid Pharmaceutical, leading to a temporary suspension of its stock [6] - Beijing has launched a free HPV vaccination program for new first-year junior high school girls, aiming to increase vaccination rates [7][8] - Two studies on iza-bren (EGFR×HER3 dual antibody ADC) have been selected for the official news release program at the 2025 WCLC, highlighting its clinical significance [9] Group 4: Shareholder Actions - Chengda Pharmaceutical announced that a shareholder plans to reduce their stake by up to 7.27% within three months [10] - Kangchen Pharmaceutical's controlling shareholder plans to reduce their stake by up to 3% between September 29 and December 28, 2025, due to personal funding needs [11]